Canakinumab
- PDF / 169,027 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 3 Downloads / 122 Views
1 S
Thrombocytopenia: case report In a study aimed to investigate the efficacy and safety of anti-Interleukin-1 agent in paediatric patients, a patient [sex and exact age not stated] was described, who developed thrombocytopenia, while receiving canakinumab for familial mediterranean fever (FMF). The patient, who had FMF, started receiving anti-interleukin-1 therapy with canakinumab [dosage and routes not stated]. However, the patient developed thrombocytopenia secondary to canakinumab [duration of treatment to reaction onset not stated]. Canakinumab was temporarily discontinued resulting in resolution of thrombocytopenia. Sag E, et al. Anti-IL1 treatment in colchicine resistant pediatric fmf patients-real life data from the helios registry. Annals of the Rheumatic Diseases 79 (Suppl.): 179-180 803516031 abstr. OP0288, Jun 2020. Available from: URL: https://ard.bmj.com/content/annrheumdis/79/Suppl_1/179.1.full.pdf [abstract]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
